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The factors governing interindividual variability in disease progression among children verti-
cally infected with human immunodeficiency virus type 1 (HIV-1) remain unclear. Because it has
recently been shown in infected adults that the density of CC chemokine receptor 5 (CCR5) mol-
ecules at the surface of nonactivated (human leukocyte antigen [HLA]–DR2) CD4+ T cells corre-
lates with disease progression, the same correlation was sought in children. HLA-DR2CD4+ T cell
surface CCR5 density was constant over time and correlated with the bioclinical stage and with
the CD4 cell slope observed before antiretroviral treatment. In addition, CCR5 density was nega-
tively correlated with the intensity of the decrease in viremia during antiretroviral therapy and
was positively correlated with CD4 cell slope since birth. These results are compatible with the
hypothesis that CCR5 density is a key factor governing disease progression in pediatric HIV-1 in-
fection and, thereby, an indicator of prognosis. Moreover, they suggest that therapies aimed at
reducing CCR5 accessibility should slow down HIV disease evolution in children.
The course of human immunodeficiency virus type 1 (HIV-1)
infection is highly variable among vertically infected children.
One-third of them will develop AIDS during their first year of
life, whereas the others will have more slowly progressing dis-
ease, with a few even remaining asymptomatic for several years
[1]. Although a high level of HIV RNA in plasma has been
correlated with disease progression, its predictive value for an
individual child is only moderate because of a marked overlap
in levels of viremia between those with rapid and slow progres-
sion, particularly during the first year of life [2, 3]. Understanding
the factors governing the evolution of HIV-1 infection in chil-
dren is a major goal for defining strategies to slow down this
evolution. Yet, the reasons for this interindividual variability are
poorly understood.
Most HIV-1 strains transmitted from mother to infant use the
CC chemokine receptor 5 (CCR5) rather than the CXC chemo-
kine receptor 4 (CXCR4) coreceptor [4, 5]. CCR5 and CXCR4
are chemokine receptors belonging to the G protein–coupled
receptor superfamily. In vitro, the mean number of CCR5 mole-
cules on the surface of the target cell (CCR5 density) determines
its infectability by CCR5-using (R5) strains [6–9]. We have
recently shown among infected adults that CCR5 density is cor-
related with the level of R5 virus RNA in plasma [10] and with
the rate of CD4+ T cell loss [11]. The present study was aimed
at testing the hypothesis that, similarly, CCR5 density could
govern the course of HIV-1 infection in vertically infected chil-
dren. To test this hypothesis, we looked for a correlation be-
tween CCR5 expression and bioclinical evolution in a group of
40 infected children.
Subjects and Methods
Study subjects. All children (20 of each sex) vertically infected
with HIV-1 who were being monitored at university hospitals in
Geneva, Switzerland, and Montpellier, France, were recruited for
this study. They ranged in age from 10 to 201 months (arithmetic
mean, 108 months; 95% confidence interval [CI], 92–123). At each
visit (1 visit per child; 2 visits if CCR5 density or virus load was
being monitored), blood was drawn, CD4 cell count was determined,
and the plasma HIV RNA level was quantified by a commercial
assay (Amplicor HIV-1 Monitor, version 1.5; Roche Diagnostic
Systems) according to the manufacturer’s instructions. This assay
was selected for its ability to quantitate HIV RNA from various sub-
types, including non-B subtypes. Children were classified in clinical
classes N, A, B, and C and biologic classes 1–3 according to the
1994 recommendations of the Centers for Disease Control and Pre-
vention for children [12]. Ten percent were in class N (age range, 5–
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Table 1. Bioclinical characteristics of children vertically infected with human immunodeficiency virus type 1 (HIV-1) in study of CC chemokine receptor 5 (CCR5) density on CD4+
T cell surface and disease progression.
Patient
Age at
recruitment,
years
CDC stage
before
treatment
CD4+ T cell
slope before
treatment, % of
cells lost/year
Current CD4+
T cell slope,
% of cells
lost/year
CCR5
genotype
CD4+
T cells
expressing
HLA-DR, %
DR2CD4+
T cells
expressing
CCR5, %
Total CD4+
T cells
expressing
CCR5, %
CCR5
density on
DR2CD4+
T cellsa
CCR5
density on
total CD4+
T cellsa
DR2CD4+
T cells
expressing
CXCR4, %
Total CD4+
T cells
expressing
CXCR4, %
CXCR4
density on
DR2CD4+
T cellsa
CXCR4
density on
total CD4+
T cellsa
Viral
phenotype
1 15 B2 1.2 1.2 WT/WT 29 6 14 8432 8669 10 10 2562 3128 NSI
2 7 B1 7.2 0.7 WT/WT 5 5 8 5939 6468 9 1 2219 1991 SI
3 15 A2 3.4 1.6 WT/WT 7 11 13 8575 6684 1 1 2346 1811 NSI
4 9 B1 1.5 1.1 WT/WT 6 9 12 9880 12,198 20 19 2527 1615 NSI
5 5 B3 66.0 4.5 WT/WT 9 28 35 18,556 14,907 1 1 2548 2170 N
6 5 N2 50.0 2.6 WT/WT 11 34 40 13,433 11,216 11 11 2579 2394 NSI
7 4 A1 7.2 2.9 WT/WT 10 16 21 7244 5316 5 5 2045 1823 ND
8 11 B3 4.9 2.4 WT/WT 9 13 16 12,572 13,194 8 8 4817 2464 N
9 12 A2 1.9 1.8 WT/WT 7 19 22 13,582 11,602 11 10 2334 2830 NSI
10 12 A2 ND 1.3 D32/WT 2 5 6 8230 7088 1 1 4303 3127 SI
11 9 A3 6.3 1.4 WT/WT 4 9 12 12,714 9632 2 1 3375 3262 SI
12 14 B2 4.9 1.5 WT/WT 39 9 19 6921 5868 7 5 5644 4076 ND
13 7 N1 2.2 1.3 WT/WT 13 19 26 6316 5066 5 5 3281 3262 NSI
14 5 N1 2.7 1.3 WT/WT 24 50 62 5308 4852 5 5 5374 3452 N
15 ,1 C1 ND ND WT/WT 8 12 18 6716 6058 8 10 3745 2912 NSI
16 11 A2 3.6 1.8 WT/WT 28 18 25 7826 6272 10 9 5226 3626 NSI
17 12 B1 8.8 8.8 WT/WT 24 52 56 8443 7012 8 7 3254 2517 NSI
18 14 A3 2.9 1.2 WT/WT 17 27 34 9910 11,508 2 2 4251 3516 NSI
19 7 A1 13.3 2.0 WT/WT 32 26 41 5355 4907 12 9 4365 2978 NSI
20 8 A3 ND 0.6 WT/WT 4 9 12 8198 8990 35 35 2725 2782 N
21 9 A2 13.8 2.4 WT/WT 22 24 38 13,672 15,322 34 29 3103 3781 ND
22 6 B3 48.0 4.5 WT/WT 12 11 17 13,357 14,567 40 40 7848 8025 NSI
23 3 A1 33.0 1.1 WT/WT 6 11 15 10,465 10,838 43 42 1799 1786 ND
24 8 N1 4.9 0.0 WT/WT 4 8 10 5865 7192 38 36 1509 1502 N
25 13 A2 2.2 1.2 WT/WT 8 17 20 8999 9476 12 12 1723 1725 N
26 5 B3 12.9 2.1 WT/WT 10 10 16 9340 10,162 25 45 1682 1675 N
27 7 C3 26.4 5.0 WT/WT 59 29 59 5869 10,435 34 31 3678 3807 SI
28 9 B3 96.0 2.7 WT/WT 28 26 37 13,197 14,546 21 21 3197 3499 NSI
29 7 C3 7.8 2.7 WT/WT 9 12 16 10,976 11,394 33 32 1965 2083 N
30 7 B1 ND 1.5 WT/WT 10 5 8 7950 8738 32 30 1996 2003 ND
31 7 B1 0.0 0.0 WT/WT 4 8 10 8601 8856 ND 25 ND 2595 ND
32 3 A1 96.0 3.0 WT/WT 6 3 6 10,405 12,317 3 3 1760 1738 ND
33 10 A2 ND 0.3 WT/WT 6 10 14 11,368 12,605 35 33 2251 2264 N
34 13 A3 ND 1.4 WT/WT 15 9 18 12,030 15,312 19 26 2205 2228 NSI
35 12 B3 4.5 1.1 D32/WT 11 15 19 9465 10,279 29 30 2444 2464 SI
36 4 A1 ND 0.0 WT/WT 2 4 5 7339 7446 23 23 3099 3138 N
37 14 C3 ND 0.3 WT/WT 10 22 29 6115 8237 78 77 3891 3981 N
38 13 C3 5.0 0.9 WT/WT 11 23 33 12,756 13,744 27 24 2919 2928 N
39 3 B1 ND 1.6 WT/WT 8 5 9 6223 6903 32 30 1849 1878 ND
40 16 A3 ND 1.4 WT/WT 17 12 21 10,810 10,389 45 38 4863 4889 NSI
NOTE. CDC, Centers for Disease Control and Prevention; CXCR4, CXC chemokine receptor 4; N, negative culture; ND, not determined; NSI, non–syncytium inducing; SI, syncytium inducing; WT, wild type.
a Cell surface coreceptor density is expressed as mean no. of coreceptor molecules/cell.
8 years; mean, 6.2 years), 42.5% in class A (age range, 3–16 years;
mean, 9.6 years), 35% in class B (age range, 3–15 years; mean, 8.7
years), and 12.5% in class C (age range, 1–14 years; mean, 8.4
years). CD4 cell loss per year was evaluated for each child by calcu-
lating the difference between the percentage of CD4+ T cells (Y) and
the normal percentage of CD4+ T cells at the age of the child [13] (X)
and by dividing this difference by the age of the child in months (Z),
as follows: ½ðX  YÞ=Z £ 12. This formula is an indicator of the
progressive CD4 cell loss during the whole life of the child, result-
ing in the deficit in CD4+ T cells observed at the moment of the
study. The bioclinical characteristics of the 40 children are shown
in table 1. All of them were treated. We monitored plasma virus
load after the onset of the treatment for 21 children who received
a triple therapy consisting of 2 nucleoside agents and 1 protease
inhibitor. Nineteen age-matched healthy children (negative control
group) were recruited at the university hospital of Montpellier,
France.
CCR5 phenotyping. CD4+ T cell surface densities of CCR5 and
CXCR4 were determined by quantitative flow cytometry, as de-
scribed elsewhere [10]. For this purpose, blood cells were directly
labeled with phycoerythrin-conjugated anti-CD4 monoclonal anti-
body (MAb) and phycoerythrin–cyanin-5 anti–HLA-DR MAb
and were indirectly labeled with anti-CCR5 (2D7) or anti-CXCR4
(12G5) MAb (Pharmingen) and a fluorescein isothiocyanate–con-
jugated anti-immunoglobulin probe (H+L; Jackson ImmunoResearch
Laboratories). After gating on CD4+, CD4+DR+, or CD4+DR2 T
cells, the intensity of CCR5 or CXCR4 expression on CCR5+ or
CXCR4+ cells was analyzed by conversion of fluorescein isothio-
cyanate fluorescence into mean number of surface–bound MAb
molecules per cell, using populations of standard microbeads pre-
coated with different well-defined quantities of MAb (QIFIKIT;
Dako) and concurrently labeled with the same fluorescein isothio-
cyanate–conjugated anti-immunoglobulin probe.
CCR5 genotyping. Presence of the 32-bp deletion in the CCR5
gene (CCR5D32) was detected by polymerase chain reaction and
was confirmed by sequencing [10].
Viral phenotyping. Syncytium-inducing or non–syncytium-in-
ducing phenotype was determined by coculturing 1 £ 106 periph-
eral blood mononuclear cells from the patient with donor peripheral
blood mononuclear cells and 5 £ 106 MT2 cells in 5 mL of RPMI
1640 supplemented with 10% fetal calf serum, glutamine, and anti-
biotics. Coculture was done for 4 weeks. Virus production was
monitored by measuring the HIV-1 p24 antigen concentration in
the culture supernatant, and the presence of the syncytium-inducing
strain was determined by looking for syncytia under an inverted op-
tical microscope.
Statistical analysis. Time-course variation in CCR5 density
was analyzed on 2 measures per child with a paired version of the
Wilcoxon signed-rank test. Spearman rank correlations were used
to evaluate the link between CCR5 density and duration of infec-
tion, bioclinical stage, CD4 cell loss, and decline in viremia during
therapy. P , :05 was considered to be significant. The statistical
program InStat 2.01 (GraphPad Software) was used in analysis.
Results
DR 2CD4 + T cell surface CCR5 density is constant in the
course of pediatric HIV-1 infection. Before examining the
role of DR2CD4+ T cell surface CCR5 density in disease pro-
gression, we first determined whether this parameter was con-
stant over time in infected children, as it is in adults [10, 11].
For this purpose, we monitored the DR2CD4+ T cell surface
CCR5 density of 22 HIV-1–infected children (age range, 1–16
years), randomly chosen over a period of 12 months. DR2CD4+
T cell surface CCR5 density appeared to be unchanged during
this period, despite some individual variations (arithmetic mean
at the beginning of the study, 8718 molecules/cell [95% CI,
7298–10,140]; arithmetic mean at the end of the study, 8421
molecules/cell [95% CI, 6754–10,088]; P ¼ :603). We also
measured DR2CD4+ T cell surface CCR5 density in 19 healthy
children. In this control group, CCR5 density was not correlated
with age (r ¼ 0:164 [95% CI,20.327 to 0.585]; P ¼ :503). In
the 40 vertically infected children we studied, DR2CD4+ T cell
surface CCR5 density was also not correlated with age (r ¼
0:178 [95% CI, 20.150 to 0.472]; P ¼ :271; figure 1). Thus,
DR2CD4+ T cell surface CCR5 density appeared to be steady
over time in infected children.
DR 2CD4 + T cell surface CCR5 density is correlated with dis-
ease progression before the onset of antiretroviral therapy. To
test the hypothesis that CCR5 expression could determine the
natural course of the disease in HIV-1–infected children, we com-
pared their DR2CD4+ T cell surface CCR5 density with their
bioclinical stage before any specific treatment had been pre-
scribed (table 1). We excluded from our study children from whom
syncytium-inducing strains were isolated, because these strains
are CCR5 independent. We found a correlation between CCR5
density and severity of bioclinical disease stage before therapy.
Figure 1. Absence of correlation in vertically infected children be-
tween duration of human immunodeficiency virus type 1 infection and
DR2CD4+ T cell surface CC chemokine receptor 5 (CCR5) density.
m, months.
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Figure 2. Correlation of DR2CD4+ T cell surface CC chemokine receptor 5 (CCR5) density with bioclinical stage (A) and with CD4+ T cell
slope (B) in nontreated human immunodeficiency virus type 1–infected children.
This correlation was the strongest when clinical stage and bio-
logic stage were combined (figure 2A; r ¼ 0:638 [95% CI,
0.373 to 0.807]; P , :001). Likewise, we calculated the annual
percentage of CD4+ T cell loss in each child before the onset of
treatment and found a correlation between this CD4 cell loss
and DR2CD4+ T cell surface CCR5 density (r ¼ 0:417 [95%
CI, 0.023 to 0.698]; P ¼ :034; figure 2B). This correlation was
logarithmic. Under a threshold of 10,000 CCR5 molecules
per cell, CD4 cell loss was small, and above this threshold it was
large. This correlation was independent of the presence of the
CCR5D32 deletion, which has been involved in delayed disease
progression [14–18]; the 2 children who were heterozygous for
this deletion were not included in the calculation, because they
harbored syncytium-inducing strains (table 1). On the other
hand, CD4 cell loss was linked to neither the percentage of
DR2CD4+ T cells expressing CCR5 (CCR5 frequency, r ¼ 0:222
[95% CI,20.184 to 0.564]; P¼ :265) nor the DR2CD4+ T cell
surface CXCR4 density (r ¼ 0:013 [95% CI,20.394 to 0.417];
P ¼ :949).
CD4 + T cell surface CCR5 density is correlated with the re-
sponse to antiretroviral therapy. The correlation we have estab-
lished between CCR5 density and the evolution of the infection
before treatment may be the consequence of the effect of CCR5
expression on the capacity of the target cell to sustain a productive
infection. Moreover, it is logical to assume that CCR5 density
could also influence the response to antiretroviral therapy, for
at least 2 reasons: First, viral replication in cells expressing
high densities of CCR5 molecules should be more difficult to
block than viral replication in cells expressing low CCR5 den-
sities, and, second, in high CCR5 expressers, low residual viremia
will result in the productive infection of cells with a high density
of membrane CCR5, and replication will be sustained. To test
this hypothesis, we determined the efficiency of triple antiretro-
viral therapy, including a protease inhibitor, among the 21 children
who received such treatment. Figure 3 shows that the intensity
of the decrease in HIV-1 RNA plasma level after 3 months of
treatment was correlated with DR2CD4+ T cell surface CCR5
density (r ¼20:484 [95% CI, 20.763 to 20.053]; P ¼ :026).
Here again, neither CCR5 frequency (r ¼20:187 [95% CI,
20.582 to 0.279]; P¼ :417) nor CXCR4 density (r ¼20:133
[95% CI,20.543 to 0.330]; P¼ :567) was linked to the response
to treatment.
DR 2CD4 + T cell surface CCR5 density is correlated with
disease progression beyond the onset of antiretroviral therapy.
If DR2CD4+ T cell surface CCR5 density is correlated with dis-
ease progression before the onset of antiretroviral therapy and
with the quality of the response to this treatment, it is logical
to assume that CCR5 density could determine the global course
of the disease in treated children. Consistent with this hypoth-
esis, we found a correlation between DR2CD4+ T cell surface
CCR5 density and CD4+ T cell slope since birth for all children
(r ¼ 0:415 [95% CI, 0.073 to 0.670]; P ¼ :016; figure 4). CD4+
T cell slope since birth was not linked to CCR5 frequency (r ¼
0:292 [95% CI,20.061 to 0.581]; P ¼ :093) nor to CXCR4 den-
sity (r ¼ 0:074 [95% CI,20.292 to 0.421]; P ¼ :688).
Discussion
Herein we have shown that DR2CD4+ T cell surface CCR5
density is correlated with disease progression, as shown by
Figure 3. Correlation between DR2CD4+ T cell surface CC chemokine receptor 5 (CCR5) density and response to treatment (decline in vir-
emia) among human immunodeficiency virus type 1–infected children. m, months.
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bioclinical stage, in children vertically infected with HIV-1. Our
hypothesis is that this link is due to the effect of CCR5 density
on HIV production in vitro and in vivo and thereby on CD4 cell
loss. An alternative hypothesis could be that disease progression
influences CCR5 expression. Our observation that CCR5 ex-
pression is globally stable over a period of 1 year in a group of
infected children argues against this second hypothesis. More-
over, the individual variations in CCR5 density that we observed
over time within this group were not correlated with individual
progression (data not shown). Therefore, we propose that in-
dividual CCR5 expression is one factor, among others, that in-
fluences disease progression. Of interest, herein we found the
correlation between CCR5 density and CD4 cell slope to be log-
arithmic, as was found for the correlation between CCR5 den-
sity and infectability [6] or virus load [10]. A role for CCR5 in
the course of pediatric HIV infection has been reported in previ-
ous studies; in particular, heterozygosity for CCR5D32 has been
found to be associated with slow disease progression [14–18].
Of note, CCR5D32 deletion results in the synthesis of a trun-
cated CCR5 molecule that is unable to reach the cell surface
[19]. It is possible that low CCR5 expression is the only reason
that the CCR5D32 deletion confers limited protection from dis-
ease progression in persons who are heterozygous for this de-
letion. Other factors may induce a low CCR5 expression result-
ing in slow disease progression, which would explain why we
found that CCR5 density in children devoid of the CCR5D32 de-
letion was correlated with CD4 cell loss. These factors might out-
weigh the effect of CCR5D32 heterozygosity, so that the protec-
tive effect of this deletion has not been found in other studies
[20–23]. Particularly, polymorphisms in the regulatory region
of the CCR5 gene, such as homozygosity for CCR5-59356-T,
which has been associated with an increased rate of perinatal
HIV-1 transmission [24], might influence disease progression.
We have recently explored the mechanism by which CCR5
density determines HIV production (authors’ unpublished data).
We have observed that CCR5 overexpression results in a drastic
postentry boost of the virus’s replicative cycle. We hypothesize
that HIV production is high in children presenting with high
CCR5 expression because of a high level of cell activation
mediated by viral envelope–CCR5 interaction.
In addition to being predictive of the natural course of infec-
tion, CCR5 density might also be predictive of the response to
treatment and thus of the course of the infection during treat-
ment. This observation may partially explain why some persons
(low CCR5 expressers) show a good response to treatment,
whereas others (high CCR5 expressers) show a poor response.
It also elucidates the reports on the effects of the CCR5D32 dele-
tion on the response to antiretroviral therapy [25, 26]. Quantifi-
cation of DR2CD4+ T cell surface CCR5 density could thus be
informative not only in regard to the natural prognosis, helping
in the decision of whom to treat, but also in regard to the future
response to this treatment, helping in the decision of how to
treat. This information may be particularly valuable for HIV-
infected children, because of the potential toxicity of antiretro-
viral therapies.
Reducing CCR5 density should have a doubly beneficial ef-
fect in HIV-infected patients. It should slow down disease pro-
gression and potentiate classical antiretroviral treatment. This
means that anti-CCR5 therapies could have a direct protective
effect, as well as an indirect protective effect, in synergy with
current anti-HIV drugs.
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